Cyril Amarchand Mangaldas advised Jefferies India Private Limited (Jefferies), the broker in the block sale of equity shares of Ajanta Pharma Limited (Ajanta Pharma) by Ravi Agrawal Trust and Aayush Agrawal Trust. The sale of shares was executed by way of the screen-based trading platform of the BSE and NSE for an aggregate amount of INR 650 crore.

The Capital Market Practice of Cyril Amarchand Mangaldas advised Jefferies on the transaction. The transaction team was led by Vijay Parthasarathi, Partner (Regional Co-head Markets- South); with support from Aashima Johur, Principal Associate; and Kinjal Shah, Senior Associate.

The transaction involved the sale of 58,40,071 equity shares of Ajanta Pharma comprising of 17,96,945 equity shares held by Ravi Agrawal Trust and 40,43,126 equity shares held by Aayush Agrawal Trust, by way of a share sale on the screen-based trading platform of the Stock Exchanges, for a reported aggregate amount of INR 650 million.

Other Parties and Advisors to the transaction included Jefferies India Private Limited (acted as broker) and Ashurst LLP (acted as International legal counsel for broker). The transaction was signed on 25th November 2022; and closed on 23rd December 2022.